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Introduction
The use of medical gases to treat oxidative stress is an
exciting and evolving therapeutic possibility. Oxidative
stress is the process of cellular injury caused by excessive
levels of reactive oxygen species (ROS). ROS are highly
reactive, unstable molecules generated during a variety of
energy-generating biochemical reactions and cellular
functions. ROS function as necessary signaling molecules,
critically modulate the activation of the immune system and,
thus, participate in antibacterial defense [1]. However, when
ROS formation is unbalanced in proportion to protective
antioxidants, the excess ROS can cause toxic effects that
damage all components of the cell including lipids, proteins,
and DNA and ultimately lead to cell death. Antioxidants
prevent oxidant formation or scavenge the ROS produced
under conditions of oxidative stress by binding and inacti-
vating them. Most antioxidants are electron donors and react
with ROS, which are free radicals, to form innocuous end
products, such as water.
The primary sources of oxidative injury include super-
oxide anion (·O2−) and hydrogen peroxide (H2O2), which
undoubtedly play important roles; however, these species
also produce highly reactive hydroxyl radicals (·OH) and
peroxynitrite (ONOO−) through the Haber-Weiss or Fenton
reactions [2, 3]. Oxidative stress resulting from an imbalance
between pro-oxidant and antioxidant systems, has been
implicated in many diseases including cardiovascular dis-
ease, cancer [4], chronic inflammatory disease [5], hyper-
tension [6], ischemia/reperfusion injury [7], acute respira-
tory distress syndrome (ARDS) [8], and neurodegerative
diseases such as Parkinson’s disease and Alzheimer’s
disease [9, 10], as well as in aging [11]. Exogenous admin-
istration of antioxidants has been utilized as a therapeutic
approach and there is evidence that antioxidants protect
against oxidative stress and prevent the pathological pro-
cesses of a wide range of diseases.
Medical gases are pharmaceutical gaseous molecules
which offer solutions to medical needs. They include tradi-A. Nakao et al.
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tional gases, like oxygen and nitrous oxide, as well as gases
with recently discovered roles as biological messenger
molecules including nitric oxide, carbon monoxide and
hydrogen sulphide. In this article, we will review recent
advances and current knowledge pertaining to antioxidant
medical gases including the three gaseous signaling mole-
cules (nitric oxide, carbon monoxide and hydrogen sulphide),
as well as hydrogen, xenon and ozone. Additionally, we will
discuss their clinical applications and therapeutic properties
(Table 1). These gases may be toxic, hazardous or poisonous
at a higher concentration, however; they are safe and poten-
tially therapeutic at lower concentrations. Medical gases
can be administered in a straightforward way simply by
providing the gas for the patients to inhale using a ventilator
circuit, facemask, or nasal cannula. While there are a variety
of delivery systems presently in use and even more under
development, the basic design and goal of each system is to
provide safe gas delivery and precision gas analysis or
monitoring. In addition to the development of safe devices
for inhaled medical gas, potential clinical application may
include a parenteral injectable or a drug containing a gas-
releasing moiety. Medical gas therapy is a relatively
unexplored field of medicine; however, a recent increase in
publications in the medical gas field clearly indicates that
there are significant opportunities for the use of medical
gases as therapeutic tools [12, 13].
Nitric Oxide (NO)
Nitric oxide (NO) is a colorless and poisonous gas which
is generated by automobile and thermal power plants and
causes a serious air pollutant. NO concentration in unpol-
luted air is approximately 0.01 parts per million (ppm). NO,
together with NO2, participates in damage of ozone layer by
absorbing high frequency ultraviolet light from the sun.
However, NO is an important signaling molecule in the
Table 1. Antioxidant medical gas
nitric oxide carbon monoxode hydrogen hydrogen sulphide xenon ozone
formula NO CO H2 H2SX e O 3
color, odor colorless, a mild, 
sweet odor
colorless, 
odorless
colorless, 
odorless
colorless, smell 
like rotten egg
colorless, 
odorless
pale blue a sharp, 
cold, irritating odor
receptors heme proteins 
K/Ca channel
heme proteins 
K/Ca channel
unknown KATP channels N-methyl-D-
aspartate (NMDA)
not determined
flammable no no yes yes yes no
toxicity yes yes no yes yes yes
produced in 
mammalian 
cells?
Yes. From L-
arginine by nitric 
oxide synthase 
(NOS), or 
reduction of nitrite
Yes. Through 
heme 
degradation by 
heme oxygenase
No Yes. From L-
cysteine by CBS 
and CBE
No Yes. In the white 
blood cells and 
other biological 
systems
application 
except medical 
use
rare except 
medical use
industrial fuels analytical 
chemistry
light emitting 
devise
bleaching 
substances
effects for 
vessels
vasodilation vasodilation unknown vasodilation no change vasodilation
anti-apoptotic 
effects
yes yes yes yes yes yes 
(preconditioning)
anti-inflammatory 
effects
yes yes yes yes yes yes 
(preconditioning)
therapeutic 
human use
pulmonary 
hypertension, lung 
transplantation 
ARDS
not available decompression 
sickness in divers, 
breath test for 
mal-absorption
not available general anesthesia, 
medical imaging 
(133Xe)
cancers, chronic 
fatigue syndrome, 
infectious diseaseAntioxidant Medical Gas
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body of mammals and was named “Molecule of the Year” in
1992 [14]. Inhaled NO is a relatively new United States
Food and Drug Administration (FDA) investigational drug
and numerous facilities are involved in clinical trials utilizing
NO.
In normoxic conditions, NO is synthesized endogenously
from the amino acid, L-arginine, by nitric oxide synthase
(NOS). NO is also generated by the reaction of near-
physiological levels of nitrite with deoxyhemoglobin, a
nitrite reductase, along the physiological oxygen gradient
[15]. In hypoxic or acidotic conditions, NO is generated by
reduction of nitrite. Under these conditions of very low
tissue pH and oxygen tension, nitrite may be reduced to NO
by disproportionation (acid reduction) or by the enzymatic
action of xanthine oxidoreductase (XOR) (Fig. 1) [16, 17].
The half life of NO is measured in seconds and NO is
eliminated rapidly as nitrite and nitrate in urine. Nitrite is
also considered to have a role as an endocrine pool of NO
[18].
Blood vessel dilation is one of the most well-known
effects of NO. NO stimulates soluble guanylate cyclase
(sGC) and increases cGMP content in vascular smooth
muscle cells, resulting in relaxation of vascular tone and
vasodilation. Sildenafil (Viagra®), a selective inhibitor of
phosphodiesterase type 5 (PDE5) in vascular smooth muscle,
blocks the degradation of cGMP, leading to relaxation of
blood vessels by increasing levels of cGMP. This action of
sildenafil has been used for stimulation of erections
primarily by enhancing signaling through the NO pathway
[19]. People taking nitrate medications that are converted to
NO in the body, such as nitroglycerin, are contraindicated
for PDE5 inhibitor treatment due to the potential of
overstimulating the NO-cGMP pathway. In addition to its
vasorelaxative effect, NO has a complex spectrum of actions
including the regulation of platelet activity and the
preservation of the normal structure of the vessel wall. NO,
produced by endothelial nitric oxide synthase (eNOS) in
vascular endothelial cells, activates sGC and plays a key
anti-inflammatory role by inhibiting P-selectin expression
and leukocyte recruitment [20]. Thus, the actions of NO on
blood vessels may increase tissue blood supply and abate the
inflammatory response, leading to protection of the tissues
from oxidative insults.
NO abates oxidative injury via several mechanisms. NO
reacts with peroxy and oxy radicals generated during the
process of lipid peroxidation. These peroxy and oxy radical
adducts continue the chain reactions in lipid peroxidation,
resulting in compromised cell membranes [21]. The reac-
tions between NO and these ROS can terminate lipid
peroxidation and protect tissues from ROS-induced injuries
[22]. Through the Fenton reaction, hydrogen peroxide
oxidizes iron (II) and in the process generates an extremely
reactive intermediate (the hydroxyl radical) which then
carries out oxidations of various substrates [H2O2 +F e 2+ →
Fe3+ +O H − + hydroxyl radical (·OH)]. NO prevents hydroxyl
radical formation by blocking the predominant iron catalyst
in the Fenton reaction [2]. Furthermore, NO reacts with
iron and forms an iron-nitrosyl complex, inhibiting iron’s
catalytic functions in the Fenton reaction [23]. Treatment of
rat hepatocytes with NO imparts resistance to H2O2-induced
cell death by induction of the rate-limiting antioxidant
enzyme, heme oxygenase (HO)-1 [24]. In bacteria, NO
activates the redox-sensitive transcriptional regulator
protein (OxyR), resulting in the subsequent expression of
proteins protective against ROS [25]. In addition, NO
prevents the induction of some ROS-induced genes during
tissue injury such as early growth response-1 (Egr-1), which
activates a number of adhesion molecules and accelerates
oxidative tissue injuries [26]. Thus, multiple mechanisms
underlie the antioxidant properties of NO.
Identification of the cytoprotective abilities of NO to
mitigate oxidative injuries in many model systems led to
numerous formal studies that examined the effect NO on
human patients. Multiple single-center studies demonstrated
the ability of inhaled NO to improve the outcome of patients
Fig. 1. Biological NO production in human body.
NO is generated from L-arginine by inducible nitric oxide
synthase (iNOS) and endothelial NOS (eNOS). Alterna-
tively, NO is produced from diet-derived nitrates, which
are reduced to nitrite by bacteria in the alimentary tract.
At very low tissue pH and oxygen tension, nitrite may be
reduced to NO by the enzymatic action of xanthine
oxidoreductase (XOR). Also, physiological levels of
nitrite are reduced to NO by reaction with deoxyhemo-
globin, a nitrite reductase, in the along the physiological
oxygen gradient.A. Nakao et al.
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with ARDS. NO inhalation was associated with a redistri-
bution of blood flow to well-ventilated areas in the lungs and
improved oxygen levels in the blood [27, 28]. On the other
hand, several studies showed that NO had no affects on
ARDS [27, 29]. Similarly, some studies advocate inhalation
of NO as a method to prevent graft injury due to ischemia/
reperfusion injury after human lung [30] and liver transplan-
tation [31], while others have demonstrated detrimental or
marginal effects [32–34]. Some of the adverse effects of NO
may be due to the formation of peroxynitrite (ONOO−), a
powerful pro-oxidant capable of causing organ injuries, by
reaction of NO with superoxide anion [35]. Thus, studies
examining the delivery of NO in experimental and clinical
studies have shown discrepant results. NO may be linked
both to protective and toxic effects after oxidative insults,
depending on NO levels, NO source, timing of NO
administration and the environment, suggesting a narrow
therapeutic window for NO administration in the treatment
of oxidative injuries [36].
Carbon Monoxide (CO)
CO occurs in nature as a product of oxidation or
combustion of organic matter. CO is an invisible, chemically
inert, colorless and odorless gas and is commonly viewed
as a poison. CO avidly binds to hemoglobin and forms
carboxyhemoglobin (COHb) with an affinity 240 times
higher than that of oxygen, resulting in interference with the
oxygen-carrying capacity of the blood and consequent tissue
hypoxia. COHb levels of 10–30% can cause headache,
shortness of breath and dizziness, and higher levels (30–50%)
produce deleterious toxicity, such as severe headache,
vomiting, syncope and arrhythmia, possibly death [37].
Thus, CO is widely known to be toxic at high concentra-
tions.
Similar to NO, the gaseous molecule CO is endogenously
and physiologically generated in mammalian cells via the
catabolism of heme in the rate-limiting step by heme
oxygenase (HO) systems [38]. Catabolism of heme by HO-1
is highly induced in a variety of tissues in response to
diverse stress-related conditions [39], and provides general-
ized endogenous cytoprotection [40]. The specific mecha-
nisms by which HO-1 can mediate endogenous cytoprotec-
tive functions are not clear, but byproducts generated during
the heme catabolism such as CO, iron and biliverdin, have
been suggested as potential protective mediators [41, 42].
In fact, CO, generated by HO-1 or exogenously admin-
istered, has beneficial biological and physiological func-
tions. Potent therapeutic efficacies of CO have been demon-
strated using experimental models for many conditions,
including paralytic ileus [43], hemorrhagic shock [44],
hyperoxic lung injury [45], and endotoxiemia [46],
supporting the new paradigm that, at low concentrations,
CO functions as a signaling molecule that exerts significant
cytoprotection.
Several possible mechanisms have been postulated to
explain the antioxidant effects of CO. CO binds to the heme
moiety of mitochondrial cytochrome c oxidase and substan-
tially decreases mitochondria-derived ROS [47,  48].
Additionally, this inhibition of mitochondria-derived ROS
can result in low level ROS generation and trigger adaptive
responses and cell survival, a novel mechanism to explain
redox signaling by CO [49–51]. The strong affinity of CO
for the heme moiety of other heme-containing proteins
(referred to collectively as heme proteins) may also account
for the antioxidant effects afforded by CO. During
hemorrhage, hemolysis, or ischemia/reperfusion injury,
damaged heme proteins are prone to degrade and release
heme, which is highly lipophilic and detrimental. Heme can
directly induce tissue injury by rapidly promoting peroxida-
tion of the lipid membranes of the cells [52, 53]. Further-
more, free heme derived from degraded heme proteins
during cellular injury is implicated as the source of catalytic
iron that would participate in the Fenton reaction, converting
H2O2 to more reactive hydroxyl radicals and promoting
severe tissue damage by propagating lipid peroxidation. CO
may prevent the degradation of heme proteins by binding to
the heme moiety.
Cytochrome P450s (CYP), a large group of heme proteins
which are abundant in many organs, are prone to degrada-
tion and the release heme and iron and play a critical roles
during organ injury by various insults (Fig. 2) [54–62].
Recently, our group demonstrated that CO in the organ
preservation solution used during transplantation can bind
to and stabilize renal CYP and prevent CYP degradation
and detrimental heme/iron release in renal grafts. This
resulted in potent protection from transplant-induced
ischemia/reperfusion injury [63]. Syngenic orthotopic kidney
transplantation (KTx) with 24 h cold ischemia in UW
solution (Viaspan®, Du Pont, Wilmington, DE) was per-
formed using inbred male LEW (RT.1l) rats. The excised
graft was flushed with and preserved in UW or CO-
supplemented UW (CO content; 40.6 ± 1.6 μmol/L). The
graft functions treated in UW with CO showed better renal
functions and fewer inflammatory events. The grafts stored
in control preservation solution exhibited a markedly
decreased total CYP levels in rat kidney 3 h after reperfu-
sion, indicating CYP degradation during ischemia/reperfu-
sion injury [63]. In contrast, the grafts stored in UW with CO
maintained CYP enzyme at the levels comparable to those
seen in normal kidney [63]. These data indicate that ex vivo
organ-targeted CO delivery during cold storage prevents
CYP breakdown during the ischemia/reperfusion process.
In addition to its oxidative abilities, described above, free
heme activates vascular endothelial cells and upregulates
adhesion molecules such as intercellular adhesion moleculeAntioxidant Medical Gas
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(ICAM)-1 and E-selectin. These heme-induced adhesive
events cause massive cellular infiltration and increased
vascular permeability, contributing to the pathogenesis of
local inflammatory processes by induction of monocyte
chemoattractant protein (MCP-1) and nuclear factor (NF)-
kappaB [64]. To cope with the problems caused by high
free heme concentrations, the body is equipped with various
defense mechanisms, namely the HO system. CO treatment
can induce HO-1 in cells to protect against injury [65–67].
Thus, a detrimental excess of heme can be immediately
removed by HO-1 enzymatic activity, induced by CO. The
adverse effects of inhaled CO are a major concern for
clinical use. CO combines with hemoglobin, interferes with
the oxygen-carrying capacity of the blood and leads to tissue
hypoxia. Soluble forms of CO, such as CO-releasing
molecules, may overcome this problem and allow clinical
application [68, 69]. Currently, several human clinical trials
are ongoing for various pathophysiologic disease states
testing the therapeutic effects of inhaled CO administered at
concentrations similar to those used in animal transplanta-
tion models [70, 71]. A recent study demonstrated that the
application of CO to animals at low concentrations approxi-
mating cigarette-smoke exposure caused no apparent lung
pathology [72]. However, Myer et al. failed to obtain similar
anti-inflammatory effects of CO in a human endotoxemia
model as were seen in small and large animal experiments
[71]. These discrepancies may be attributed to species-
specific differences in the affinity of CO for hemoglobin, or
physiological differences such as respiratory rate and
sensitivity to lipopolysaccharides (endotoxins) [73, 74].
Hydrogen (H2)
Hydrogen (H2) is the lightest and most abundant of
chemical elements, constituting nearly 90% of the universe’s
elemental mass. In contrast, earth’s atmosphere contains
less that 1 ppm of hydrogen. In concentrations over 5%,
hydrogen can form explosive mixtures with air, as typified
by the 1937 Hindenberg Zeppelin disaster. Although
hydrogen is known to be highly flammable and to violently
react with oxidizing elements, it is noteworthy that hydrogen
has no risk of explosion at concentrations less than 4.6%
(Safety and Standard for hydrogen and hydrogen systems;
National Aeronautics and Space Administration “NASA”,
1997). Hydrogen has wide applications in physics and
engineering. As hydrogen is a highly potent energy source,
the industrial use of hydrogen is expanding, such as the use
of hydrogen fuel cells for zero-emission vehicles.
In fact, hydrogen is physiologically and continuously
produced in our body during fermentation of non-digestible
carbohydrates, primarily in the large intestine, by numerous
strains of intestinal bacteria and is excreted as flatus, further
metabolized by flora or exhaled as a natural component of
abdominal gas [75,  76], the basis for the routinely-used
hydrogen breath test for gastrointestinal transit [77,  78].
Increased excretion of hydrogen in the breath after
carbohydrate ingestion is considered a consequence of
bacterial fermentation in the colon [79, 80]. Hydrogen gas
is routinely administered to divers as hydreliox, which
contains 49% hydrogen [81].
Gharib  et al. reported that animals maintained in a
hydrogen-supplemented hyperbaric chamber were signifi-
Fig. 2. Hypothetic scheme for the binding of CO to the heme moiety of cytochrome P450.
Cytochrome P450 (CYP) proteins are susceptible to oxidative stress and are liable to degrade and release prooxidant heme
during cellular damage. CO may bind in the heme pocket of CYP and stabilize CYP, thereby prevent CYP degradation.A. Nakao et al.
J. Clin. Biochem. Nutr.
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cantly protected from schistosomiasis-associated chronic
liver injury [82]. Hydrogen treatment significantly increased
antioxidant enzyme activity, decreased lipid peroxide levels
and decreased circulating proinflammatory cytokine levels.
Consistent with this first report showing the antioxidant
effect of hydrogen, Ohsawa et al. demonstrated that inhaled
hydrogen gas (~4%) has antioxidant and anti-apoptotic
properties that can protect the brain against ischemia-
induced injury and stroke by selectively neutralizing the
detrimental ROS [83]. Hydrogen selectively reduces the
levels of hydroxyl radicals (·OH) mainly generated through
the Fenton reaction and peroxynitrite (ONOO−)  in vitro
(Fig. 3). This report also suggests that hydrogen easily
crosses the brain-blood barrier and can be safely admin-
istered to human patients [81]. More recently, our group has
shown that hydrogen treatment ameliorates transplant-
induced intestinal injuries including mucosal erosion and
mucosal barrier breakdown. Perioperative inhalation of
2% hydrogen mitigated intestinal dysmotility following
transplantation and reduced upregulation of inflammatory
mediators, such as chemokine (C-C motif) ligand 2 (CCL2),
interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α.
Hydrogen significantly diminished lipid peroxidation
compared to air-treated grafts, as indicated by elevated
levels of malondialdehyde, a lipid peroxidation product, in
air-treated grafts demonstrating an antioxidant effect of
hydrogen [84]. Thus, treatment with hydrogen has several
potential advantages over current therapies used for
ischemia/reperfusion or oxidative injury.
The positive results of our experiments with CO inhala-
tion and hydrogen inhalation alone led us to conduct experi-
ments toward potentially more potent therapeutic gas
strategy combined CO and hydrogen. The rationale behind
this approach was based on our unpublished data and on
previous observations demonstrating several differences in
the biological actions of CO and hydrogen, even though both
ameliorate cardiac cold IRI [85, 86]. There is no chemical
reaction between CO and hydrogen at room temperature,
and the gases can be administered together safely. The
combined effects of CO and hydrogen were evaluated using
our established model of cold ischemia/reperfusion injury.
In this model, syngeneic heart transplantation (HTx) is
conducted from Lewis (RT1l) rats to Lewis rats with 18 h of
cold ischemic time in Celsior® (Pasteur Merieux Serums et
Vaccins, Lyon, France). HTx is performed into the abdomen
by anastomosing the graft aorta and recipient infrarenal
aorta and the graft pulmonary artery and recipient inferior
vena cava in an end-to-side manner [86, 87]. Myocardial
injury is evaluated by measurement of the ischemic area
of the grafts as visualized by 2,3,5-triphenyltetrazolium
chloride (TTC) staining 3 h after reperfusion [87, 88]. Cold
ischemia/reperfusion injury results in significant damage to
the cardiomyocytes. However, when both donor and
recipient were treated with mixed gas therapy with 250 ppm
of CO, 2% hydrogen in balanced air, the ischemic area was
significantly reduced, while either CO or hydrogen alone
did not significantly decrease the infarct area compared to
untreated controls (Fig. 4). These results suggested that dual
gas therapy with CO and hydrogen may have more potent
protective effects against cardiac cold ischemia/reperfusion
injury compared to single treatment.
Fig. 3. Hydrogen scavenges hydroxyl radicals.
Hydrogen selectively neutralize hydroxyl radicals
generated by the Fenton reaction.
Fig. 4. Hydrogen inhalation reduced ischemic area following
heart grafts with prolonged cold ischemia.
The extent of gross structural damage to heart graft was
evaluated by TTC staining 3 h after reperfusion. Normal
naïve hearts had negligible infarct area. The infarct area
was significantly reduced by dual-treatment with CO
and hydrogen, while either CO or hydrogen alone did
not significantly decrease the infarct area compared to
untreated controls. (NL; normal naïve heart, HTx: heart
transplant, n = 4–5 for each group, *p<0.05 vs HTx/air).Antioxidant Medical Gas
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Hydrogen Sulphide (H2S)
Hydrogen sulphide (H2S) is a colorless, toxic and
flammable gas. It is a naturally occuring gas found in
volcanic gases and some well waters and is also responsible
for the foul odor of rotten eggs and flatulence. Toxic effects
of hydrogen sulphide in humans include eye irritation,
shortness of breath, and chest tightness at concentrations
<100 ppm [89,  90]. Exposure to hydrogen sulphide at
>1000 ppm may cause severe adverse effects, ranging from
loss of consciousness to fatality [91]. Measurement of the
concentration of thiosulfate in blood and urine is useful for
determining hydrogen sulphide poisoning [92].
Hydrogen sulphide is endogenously synthesized from
L-cysteine, a product of food-derived methionine, by
cystathiononeβ-synthase (CBS) and cyctathione-γ-lyase
(CSE) (Fig. 5). Methionine adenosyltransferase (MAT)
converts methionine to homocystine. CBS catalyses the
homocystine to cystathionine conversion. CSE, subsequently,
converts cystathionine to L-cysteine. L-cysteine is further
metabolized to hydrogen sulphide by CBS and CSE [93, 94].
Hydrogen sulphide is produced normally in vertebrates, and
is believed to help regulate body temperature and metabolic
activity at physiological concentrations [95,  96]. Also,
hydrogen sulphide exerts physiological effects in the cardio-
vascular system of vertebrates, possibly through modulation
of K+-ATP channel opening or as a cellular messenger
molecule involved vascular flow regulation [97, 98]. Recent
studies have shown that hydrogen sulphide is a physiologic
gaseous signaling molecule, as are NO and CO [12].
Administration of hydrogen sulphide produced a
“suspended animation-like” metabolic status with hypo-
thermia and reduced oxygen demand in pigs (who received
it intravenously) [99] and mice (who received hydrogen
sulphide via inhalation) [100,  101], thus protecting from
lethal hypoxia. This hypometabolic state, which resembles
hibernation, induced by hydrogen sulphide may contribute
to tolerance against oxidative stress.
Some of the antioxidant effects of hydrogen sulphide can
be explained by its effects on cytochome c oxidase and
mitochondrial functions, while its effects on gene expression
may be related to actions on the the NFkB and extracellular
signal-regulated kinase (ERK) pathways [102]. Cardiac
protection from oxidative injury is, at least in part, due to the
ability of hydrogen sulphide to activate myocardial KATP
channels, although this is still being elucidated [103].
Whiteman  et al. showed that hydrogen sulphide has the
potential to act as an antioxidant inhibitor of peroxynitrite-
mediated processes via activation of N-methyl-D-aspartate
(NMDA) receptors [104]. Kimura et al. revealed that
hydrogen sulphide can shield cultured neurons from oxida-
tive damage by increasing levels of glutathione, an anti-
oxidant enzyme [105]. Similarly, hydrogen sulphide can
induce upregulation of HO-1, anti-inflammatory and cyto-
protective genes [102, 106]. Hydrogen sulphide also inhibits
myeloperoxidase and destroys H2O2 [107] and can reduce
ischemia/reperfusion-induced apoptosis via reduction of
cleaved caspase-3 and cleaved poly (ADP-ribose) poly-
merase (PARP) [108]. Thus, multiple mechanisms may be
involved in the antioxidant properties of hydrogen sulphide.
Xenon
Xenon is a noble gas considered chemically inert and
unable to form componds with other molecules. Xenon is a
trace gas in Earth’s atmosphere, occurring at <0.001 ppm
and is also found in gases emitted from some mineral
springs. Xenon is not a “greenhouse gas” and,in fact, is
viewed as enviromentally friendly gas [109].
Xenon possesses anesthetic properties in animals and
humans [109–111]. Since Cullen first used xenon on human
patients in 1951, xenon has been successfully used in a
number of surgical operations [110]. Although the cost of
xenon has been too high to be used routinely in surgical
practice, xenon anesthesia systems are still being proposed
and designed for certain cases of patients, as xenon has
several advantages including greater circulatory stability,
Fig. 5. Enzymatic pathways for hydrogen sulphide production.
MAT; methionine adenosyltransferase, CBS; cystathiononeβ-
synthase, CSE; cyctathione-γ-lyaseA. Nakao et al.
J. Clin. Biochem. Nutr.
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lower analgesic consumption, lower adrenaline levels and
better regional perfusion of individual organs [109, 112].
Xenon readily crosses the blood-brain barrier and has low
blood/gas solubility, which is advantageous for rapid inflow
and washout [113]. Human patients anaesthetized with
xenon show good cardiovascular stability and satisfactory
sedation [111]. Also, xenon inhalation had no measurable
effects on mesenteric vascular resistance in the propofol-
sedated pig [114].
In addition to its anesthetic properties, xenon has protec-
tive effects against cerebral ischemia [115]. Decreased blood
flow to the brain leads to neuronal death through necrotic
and apoptotic mechanisms, which are largely dependent on
the activation of the NMDA receptor [116]. Since xenon
effectively inhibits the NMDA receptor, the neuroprotective
effects of xenon may be at least partially due to this inhibi-
tion [115, 117–119]. Similarly, Abraini et al. showed that
xenon reduced ischemia-induced neuronal death induced by
occlusion of the middle cerebral artery in rodents, and
decreased NMDA-induced Ca2+ influx, a critical event
involved in excitotoxicity, in neuronal cell cultures [120].
Also, xenon has inhibitory effects on the Ca2+-ATPase pump
and interferes with the Ca2+ intracellular signaling pathway,
which might also be involved in the prevention of ischemic
injury [121].
There is evidence suggesting that brief exposure to xenon
prevents myocardial ischemia/reperfusion injury [122].
Although exact mechanism involved in prevention of
ischemia-induced myocardial injury are still not fully
elucidated, xenon significantly activates protein kinase C
(PKC)-epsilon and leads to phosphorylation of p38 mitogen-
activated protein kinase (MAPK). This signaling may
represent a central molecular mechanism for xenon’s
protective effects [122,  123]. Interestingly, other noble
gases, such as helium, neon and argon, have also been shown
to convey protection against cardiac ischemia/reperfusion
injury [124].
Ozone
Ozone is a triatomic molecule, consisting of three oxygen
atoms. Ozone is a pale blue gas with a sharp, cold, irritating
odor and is produced naturally by electrical discharges
following thunderstorms or ultraviolet (UV) rays emitted
from the sun. Ozone is present in low concentrations
throughout the Earth’s atmosphere; however, an ozone layer
exists between 10 km and 50 km above from the surface of
the earth and plays a very important role filtering UV rays
which is critical for the maintenance of biological balance in
the biosphere [125, 126]. Ozone gas has a high oxidation
potential and is used in as an antimicrobial agent against
bacteria, viruses, fungi, and protozoa. In particular, supple-
mentation of ozone into spas and hot tubs can reduce the
amount of chlorine or bromine required to maintain cleanli-
ness by reactivating chlorine and bromine to their free states.
Also, ozone is also widely used in treatment of water in
aquariums and fish ponds to minimize bacterial growth,
control parasites, and eliminate transmission of some
diseases. Ozone inhalation (0.1 to 1 ppm) can be toxic to the
pulmonary system and cause upper respiratory irritation,
rhinitis, headache, and occasionally nausea and vomiting.
Ozone, administered by rectal insufflation, prior to
ischemia/reperfusion injury, prevents the damage induced
by ROS and attenuate renal and hepaticischemia/reperfusion
injury [127–129]. It is postulated that ozone could prepare
the host to face physiopathological events mediated by ROS,
through NO-related mechanisms by modulating increases in
eNOS and iNOS expression [127, 130, 131]. In addition,
ozone has vasodilative effects without affecting any other
cardiopulmonary parameters [132]. Al-Dalain et al.
demonstrated that the ozone treatment improved glycemic
control and prevented oxidative stress in diabetic rats.
This study suggested that repeated administration of ozone
in non-toxic doses might play a role in the control of
diabetes and its complications [133]. Medical applications
of blood ozonation via extracorporeal blood oxygenation
and ozonation (EBOO) was found to be safe and effective
in treating peripheral artery disease in clinical trials [126,
134–136].
Conclusion
As highlighted above, the ability of medical gases to
ameliorate oxidative stress plays important roles at the
chemical, cellular and physiological levels. Although some
medical gases may cause serious adverse effects, there are
still many possible applications of these gases as therapeutic
tools for various diseases if the concentrations are tightly
controlled. The future of medical gas therapy must focus on
the establishment of safe and well-defined administration
parameters and on randomized controlled trials to determine
the precise indications and guidelines for the use of medical
gases in the treatment of various pathologies.
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